259 related articles for article (PubMed ID: 28460340)
1. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
Medaglini D; Siegrist CA
Curr Opin Virol; 2017 Apr; 23():88-94. PubMed ID: 28460340
[TBL] [Abstract][Full Text] [Related]
2. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.
Farooq F; Beck K; Paolino KM; Phillips R; Waters NC; Regules JA; Bergmann-Leitner ES
Sci Rep; 2016 Jun; 6():27944. PubMed ID: 27323685
[TBL] [Abstract][Full Text] [Related]
3. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
4. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
6. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
[TBL] [Abstract][Full Text] [Related]
8. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
Huttner A; Siegrist CA
Expert Rev Vaccines; 2018 Dec; 17(12):1105-1110. PubMed ID: 30422031
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.
Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP
Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Ehrhardt SA; Zehner M; Krähling V; Cohen-Dvashi H; Kreer C; Elad N; Gruell H; Ercanoglu MS; Schommers P; Gieselmann L; Eggeling R; Dahlke C; Wolf T; Pfeifer N; Addo MM; Diskin R; Becker S; Klein F
Nat Med; 2019 Oct; 25(10):1589-1600. PubMed ID: 31591605
[TBL] [Abstract][Full Text] [Related]
13. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
[TBL] [Abstract][Full Text] [Related]
14. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
[TBL] [Abstract][Full Text] [Related]
17. Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.
Kasereka MC; Ericson AD; Conroy AL; Tumba L; Mwesha OD; Hawkes MT
Vaccine; 2020 Mar; 38(14):3003-3007. PubMed ID: 32093984
[TBL] [Abstract][Full Text] [Related]
18. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
Matz KM; Marzi A; Feldmann H
Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
[No Abstract] [Full Text] [Related]
19. Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.
Gélinas JF; Azizi H; Kiesslich S; Lanthier S; Perdersen J; Chahal PS; Ansorge S; Kobinger G; Gilbert R; Kamen AA
Vaccine; 2019 Oct; 37(44):6624-6632. PubMed ID: 31548015
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
